Search details
1.
Liposomal amphotericin B exposure in critically ill patients: a prospective pharmacokinetic study.
Med Mycol
; 60(10)2022 Oct 12.
Article
in English
| MEDLINE | ID: mdl-36124725
2.
Exposure to intravenous posaconazole in critically ill patients with influenza: A pharmacokinetic analysis of the POSA-FLU study.
Mycoses
; 65(6): 656-660, 2022 Jun.
Article
in English
| MEDLINE | ID: mdl-35437848
3.
Ultra-performance liquid chromatography for quantification of amphotericin B plasma concentrations after use of liposomal amphotericin B.
J Antimicrob Chemother
; 76(4): 961-966, 2021 03 12.
Article
in English
| MEDLINE | ID: mdl-33351897
4.
Pharmacokinetics and target attainment of intravenous posaconazole in critically ill patients during extracorporeal membrane oxygenation.
J Antimicrob Chemother
; 76(5): 1234-1241, 2021 04 13.
Article
in English
| MEDLINE | ID: mdl-33517360
5.
A Population Pharmacokinetic Modeling and Simulation Study of Posaconazole Oral Suspension in Immunocompromised Pediatric Patients: A Short Communication.
Ther Drug Monit
; 43(4): 512-518, 2021 08 01.
Article
in English
| MEDLINE | ID: mdl-33560094
6.
Interaction between flucloxacillin and azoles: Is isavuconazole next?
Mycoses
; 64(12): 1508-1511, 2021 Dec.
Article
in English
| MEDLINE | ID: mdl-34553797
7.
Concomitant use of isavuconazole and CYP3A4/5 inducers: Where pharmacogenetics meets pharmacokinetics.
Mycoses
; 64(9): 1111-1116, 2021 Sep.
Article
in English
| MEDLINE | ID: mdl-33963620
8.
Development and External Validation of an Online Clinical Prediction Model for Augmented Renal Clearance in Adult Mixed Critically Ill Patients: The Augmented Renal Clearance Predictor.
Crit Care Med
; 48(12): e1260-e1268, 2020 12.
Article
in English
| MEDLINE | ID: mdl-33048900
9.
Outpatient parenteral antifungal therapy (OPAT) for invasive fungal infections with intermittent dosing of liposomal amphotericin B.
Med Mycol
; 58(7): 874-880, 2020 Oct 01.
Article
in English
| MEDLINE | ID: mdl-31965178
10.
Antifungal drugs: What brings the future?
Med Mycol
; 57(Supplement_3): S328-S343, 2019 Jun 01.
Article
in English
| MEDLINE | ID: mdl-31292663
11.
Comment on: Isavuconazole plasma concentrations in critically ill patients during extracorporeal membrane oxygenation.
J Antimicrob Chemother
; 77(12): 3526-3527, 2022 11 28.
Article
in English
| MEDLINE | ID: mdl-36124899
12.
The impact of extracorporeal membrane oxygenation on the exposure to isavuconazole: a plea for thorough pharmacokinetic evaluation.
Crit Care
; 26(1): 227, 2022 07 27.
Article
in English
| MEDLINE | ID: mdl-35897020
13.
Fluconazole Underexposure in Critically Ill Patients: a Matter of Using the Right Targets?
Antimicrob Agents Chemother
; 65(6)2021 05 18.
Article
in English
| MEDLINE | ID: mdl-33782011
14.
Letermovir exposure in transplant patients with end-stage renal disease on renal replacement therapy.
J Antimicrob Chemother
; 76(12): 3322-3325, 2021 11 12.
Article
in English
| MEDLINE | ID: mdl-34473284
15.
Bayesian Vancomycin Model Selection for Therapeutic Drug Monitoring in Neonates.
Clin Pharmacokinet
; 63(3): 367-380, 2024 03.
Article
in English
| MEDLINE | ID: mdl-38416322
16.
Meropenem Target Attainment and Population Pharmacokinetics in Critically Ill Septic Patients with Preserved or Increased Renal Function.
Infect Drug Resist
; 15: 53-62, 2022.
Article
in English
| MEDLINE | ID: mdl-35035223
17.
Isavuconazole in the Treatment of Aspergillus fumigatus Fracture-Related Infection: Case Report and Literature Review.
Antibiotics (Basel)
; 11(3)2022 Mar 05.
Article
in English
| MEDLINE | ID: mdl-35326807
18.
Pharmacokinetic/Pharmacodynamic Target Attainment Based on Measured versus Predicted Unbound Ceftriaxone Concentrations in Critically Ill Patients with Pneumonia: An Observational Cohort Study.
Antibiotics (Basel)
; 10(5)2021 May 11.
Article
in English
| MEDLINE | ID: mdl-34064676
19.
Pharmacokinetic Variability and Target Attainment of Fluconazole in Critically Ill Patients.
Microorganisms
; 9(10)2021 Sep 30.
Article
in English
| MEDLINE | ID: mdl-34683388
20.
Concomitant Treatment with Voriconazole and Flucloxacillin: A Combination to Avoid.
Antibiotics (Basel)
; 10(9)2021 Sep 15.
Article
in English
| MEDLINE | ID: mdl-34572694